The FDA has approved an orally disintegrating tablet (ODT) formulation of rimegepant (Nurtec ODT – Biohaven), a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”), for acute treatment of migraine with or without aura in adults. Rimegepant is the second oral gepant to become available in the US; ubrogepant (Ubrelvy), which is approved for the same indication, was the first.1 Four parenteral CGRP antagonists, erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti), are approved for prevention of migraine.2,3
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine. JAMA. 2020;324(9):890–891. doi:10.1001/jama.2020.8493
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: